Ryan Smith, DO
Cardiovascular Disease · Kaneohe, HINPI 1639157365
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $109,263 of the $124,763 with a category attached, or 87.6%. 24 manufacturers reported payments, led by Amgen at 55.4% of the total. Reporting peaked in 2019 at $46,741 and has fallen 85.0% since, to $7,023 in 2025. Among cardiovascular disease clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $440.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$69K
- Esperion Therapeutics, Inc.$28K
- Novartis$20K
- Medtronic$2K
- Boston Scientific$2K
- Edwards Lifesciences$1K
- plus $2K from 18 others
Across 1 payment — averaging $210.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$210
What the payments were for
- Speaking & faculty fees$109,26388%
- Travel & lodging$4,4714%
- Food & beverage$11,0189%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 83 | $69,115 |
| Esperion Therapeutics, Inc. | 22 | $27,779 |
| Novartis | 49 | $19,923 |
| Medtronic(2 entities) | 28 | $2,350 |
| Boston Scientific | 33 | $2,092 |
| Edwards Lifesciences | 8 | $1,051 |
| Abiomed | 6 | $620 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $253 |
| Abbott | 2 | $250 |
| Boehringer Ingelheim | 7 | $172 |
| Bayer | 9 | $169 |
| E.r. Squibb & Sons, L.L.C. | 6 | $137 |
| Biotronik Inc. | 1 | $136 |
| Bard Peripheral Vascular, Inc. | 1 | $136 |
| Siemens Medical Solutions USA, Inc. | 1 | $124 |
| Pfizer | 6 | $118 |
| Johnson & Johnson | 6 | $101 |
| Terumo Medical Corporation | 1 | $86 |
| Alnylam Pharmaceuticals Inc. | 2 | $55 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$68,223
- NEXLIZET$27,757
- NEXLETOL$27,757
- ENTRESTO$19,144
- VenaSeal$1,300
- SAPIEN 3 Ultra RESILIA$745
- Impella$461
- ACCOLADE SR$289
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$273
- BodyGuardian$165
- GENERAL - THERAPIES$148
- RESONATE EL ICD VR$144
- WATCHMAN Access System$138
- LifeVest$129
- Allure Quadra RF CRT Pacemaker$129
- Reveal LINQ$125
- Micra$124
- Cios Alpha$124
- Fortify Assura, Ellipse ICD$121
- ARCTIC FRONT ADVANCE$119
How this compares
$124,763 in reported general payments places this provider in the 95th percentile of 73 cardiovascular disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 30 | $785,864 |
| EliquisApixaban | 380 | $509,176 |
| EntrestoSacubitril/Valsartan | 172 | $249,334 |
| Repatha SureclickEvolocumab | 159 | $182,977 |
| JardianceEmpagliflozin | 105 | $137,665 |
| NexlizetBempedoic Acid/Ezetimibe | 72 | $64,979 |
| VascepaIcosapent Ethyl | 54 | $53,780 |
| XareltoRivaroxaban | 50 | $42,201 |
| KerendiaFinerenone | 16 | $29,485 |
| BrilintaTicagrelor | 17 | $16,647 |
| Repatha PushtronexEvolocumab | 11 | $10,023 |
| Ezetimibe | 190 | $9,428 |
| Rosuvastatin Calcium | 160 | $7,176 |
| Atorvastatin Calcium | 211 | $6,830 |
| Metoprolol Succinate | 242 | $4,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $118 | $1,295,040410 claims |
| NovartisEntresto | $19,923 | $249,334172 claims |
| Boehringer IngelheimJardiance | $172 | $137,665105 claims |
| Esperion Therapeutics, Inc.Nexlizet | $27,779 | $64,97972 claims |
| Johnson & JohnsonXarelto | $101 | $42,20150 claims |
| BayerKerendia | $169 | $29,48516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 cardiovascular disease providers in Hawaii.
Other cardiovascular disease in Kaneohe
- Albert IngKaneohe$8K
- Dipanjan BanerjeeHonolulu$331K
- Ramy BadawiKailua$78K
- Joana MagnoHonolulu$23K
- Hingson ChunHonolulu$23K
- Sonny WongKailua$18K
- William DangHonolulu$16K
- Erin DreessensTripler Amc$14K
- Edward ShenHonolulu$12K
- Se Kon WonHonolulu$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.